Navigation Links
Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results
Date:2/13/2009

Inventories (1,703,009) 159,692 Prepayments (1,549,571) (472,365) Accounts payable 1,492,834 (1,668,080) Accounts payable - related parties (717,373) (293,176) Accrued liabilities - related party (61,824) -- Accrued liabilities 1,102,279 (150,906) Other payable (2,538,294) (313,162) Customer deposit 394,375 417,062 Payable - officer -- 31,145 Taxes payable (1,789,911) 1,671,334 Net cash (used in) provided by operating activities (878,333) 9,628,195 CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of plant and equipment (1,033) (28,455) Proceeds from equipment disposal 5,125,050 34,733 Additions to construction in progress (841,746) (5,865,225) Acquisition of land use right -- (317,183) Purchase of software program -- (5,343) Advances on plant and equipment purchase -- (5,226,396) Loan repayment from related party -- 667,950 Net cash provided by (used in) investing activities 4,282,271 (10,739,919) CASH FLOWS FROM FINANCING ACTIVITIES: Decrease in restricted cash 479,144 3,842,060 Borrowings on notes payable - banks 10,747,962 1,335,900 Payments on notes payable - banks (10,982,250) (9,084,120) Borrowings on short term loans 4,392,900 3,566,853 Payments on short term
'/>"/>
SOURCE Shengtai Pharmaceutical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Second Quarter Results of Fiscal Year 2008
2. Shengtai Pharmaceutical, Inc. Appoints New CFO
3. Shengtai Pharmaceutical Retains Grayling Global As Investor Relations Counsel
4. Shengtai Pharmaceutical Completes Factory Improvements Resulting in Operational and Environmental Benefits
5. Shengtai Pharmaceutical Schedules 2009 First Quarter Financial Results and Conference Call
6. DOV Pharmaceutical, Inc. Begins Trading on OTC Bulletin Board
7. Mindray to Present at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
9. Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation
10. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
11. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2015)... ... July 24, 2015 , ... VetStem Biopharma, proudly announces a new long term ... therapy training and clinical opportunities. , “We are very excited to be able to ... Diego area. Stem cell therapy is an established treatment for arthritic conditions in our ...
(Date:7/24/2015)... , July 24, 2015 The ... to reach USD 27.8 billion by 2022, growing at ... according to a new study by Grand View Research, ... is expected to result in significant reduction in cost ... augment adoption and usage rates of next generation sequencing ...
(Date:7/23/2015)... (PRWEB) , ... July 23, 2015 , ... Science and ... radiation, to new drug therapies and devices – according to Susan Chang, MD, director ... a session on how science and new technology are impacting the development of new ...
(Date:7/23/2015)... - Portage Biotech Inc. ("Portage") (OTC Market: PTGEF, Canadian ... Limited (Biohaven), are pleased to announce that Biohaven ... with the U.S. Food and Drug Administration (FDA) ... 54% equity interest in Biohaven, a private company. ... and Biohaven has entered into an exclusive worldwide ...
Breaking Biology Technology:VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 2VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 3Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 2Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 3Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 4Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 5Experts Present How Science and New Technology are Driving New Brain Tumor Treatments and Improving Quality of Life 2Experts Present How Science and New Technology are Driving New Brain Tumor Treatments and Improving Quality of Life 3Portage's Biohaven Announces IND Filing for BHV-0223 for Phase 1 Clinical Testing 2Portage's Biohaven Announces IND Filing for BHV-0223 for Phase 1 Clinical Testing 3Portage's Biohaven Announces IND Filing for BHV-0223 for Phase 1 Clinical Testing 4
... , RICHMOND, Va., July 31 Insmed Inc. ... that it will host a conference call on Thursday, August ... for the second quarter 2009. Insmed intends to issue ... on August 13(th). , , To participate ...
... TOKYO, July 31 R-Tech Ueno, Ltd. announced on July ... board of directors held on the day and determined the R&D ... to actively strengthen R&D in the ophthalmologic & dermatological fields that ... with external entities. , , 1. Development code ...
... , , , ... ANDS ) today announced finalization of the protocol for the ... ribavirin in hepatitis C patients. Allowance of the protocol has been ... dosing is expected to commence within the next several weeks. , ...
Cached Biology Technology:Insmed to Host Second Quarter 2009 Conference Call 2R-Tech Ueno Notifies R&D Items 2R-Tech Ueno Notifies R&D Items 3Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 2Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 3Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 4Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 5
(Date:7/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the fourth quarter and ... the close of market. The company will host a ... p.m. PT (5:00 p.m. ET), during which management may ... the live call, analysts and investors should dial 888-455-2260 ...
(Date:7/8/2015)... Summary Pancreatic cancer is the 12th ... with a mortality rate of 10.9 deaths per 100,000 ... patients has highlighted a significant need for new and ... by the current market. A highly active pancreatic ... molecule types and mechanisms of action, which provides a ...
(Date:7/7/2015)... 30, 2015 Research ... addition of the "Capacitive Fingerprint Sensors Patent ... To this date, fingerprint sensing technology is the ... sensors are well developed. This patent landscape focuses ... The domain of capacitive fingerprint sensors is ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... a complex cocktail of poisonous peptides that immobilize animal ... this cocktail damage only insects, which is why a ... a safe and ecologically sound pesticide. Prof. Michael ... has isolated the genetic sequences for important neurotoxins in ...
... the lichen Phylloblastia fortuita , new to the Iberian ... Phylloblastia dispersa , is also a new entry for ... outside the tropics. Foliicolous lichens, symbiosis between fungi ... and their presence in environments such as the Iberian Peninsula, ...
... COLUMBUS, Ohio Blocking the function of an enzyme in ... prevent nerve cells from dying after a stroke, new research ... found that the tocotrienol form of vitamin E, an alternative ... fatty acids that eventually kill neurons. The Ohio State ...
Cached Biology News:A deadly scorpion provides a safe pesticide 2A new species of lichen discovered in the Iberian Peninsula 2Study reveals how one form of natural vitamin E protects brain after stroke 2Study reveals how one form of natural vitamin E protects brain after stroke 3
... the sensitivity and versatility you expect from ... counting with selected photomultipliers ensure superior sensitivity ... with up to 2 reagent injectors the ... assays as well as other luminescence applications ...
... allows for rapid, convenient, and efficient native ... process utilizes a spin column to make ... concentration of proteins which were electro-eluted in ... ion exchangers, offering high binding capacity fo ...
MAb to HLA, Class II-DR+DP Dry Ice: No Preservative: NaN3 Availability When Not in Inventory: 14-21 Business Days...
Cell Culture Flask, nontreated polystyrene...
Biology Products: